Lumigan, Allergan’s Intraocular Pressure Drug, Received FDA Approval
The FDA has approved Allergan's once-daily prescription eye drop Lumigan as a first-line treatment for elevated intraocular pressure associated with open-angle glaucoma or ocular hypertension.
The Lumigan first-line indication is in addition to the product's already established use as a second-line treatment, for which the FDA approved the drug in 2001.
Since its introduction as a first-line treatment, Lumigan has been widely prescribed by eye care professionals to reduce elevated intraocular pressure (IOP) in patients who were intolerant of other IOP-lowering medications or who did not have a sufficient reduction in IOP in multiple measurements using other medications for the disorder.
Elevated IOP represents a major risk factor for vision loss associated with open-angle glaucoma; the higher the IOP, the greater the likelihood of optic nerve damage, which can lead to vision loss and potential blindness.
Source: Pharmaceutical-Business-Review
Filed under Eye Treatment, Glaucoma
You may also like to read
- Alcon Gets FDA Approval for Travatan-Z Which Reduce Elevated Intraocular Pressure
- Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
- IntraLase Gets Approval to Sell Femtosecond Laser System in Taiwan
- Timely Treatment Can Help To Cure Glaucoma
- Hope for Age Related Macular Degeneration with Lucentis
- Lucentis - Wet Macular Degeneration Drug is Highly Successful in Clinical Trials
- STAAR Seeks FDA Approval of Visian TICL Implantable Contact Lens For Nearsightedness and Astigmatism Treatment
- Diabetes Drug Avandia Causing Macular Edema
- Eye Drug Lucentis Recommended by UK's NICE to Treat Wet AMD
- Israel's Biotech Firm Sells Eye Treatment to Pfizer
November 3rd, 2007 at 6:14 pm
Would appreciate contact for help getting lumigan, as I have reached the limit my part D prescription insurance. I can not afford it . I have had reactions to other eye meds.